Immunic, Inc. (IMUX)
NASDAQ$1.14+0.02 (1.79%)
Market Cap
$100.89M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
294 of 924
Rank in Industry
168 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
IMUX Insider Trading Activity
IMUX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $100,369 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Rudick Richard Alan | director | 1 | $100,369 | 0 | $0 | $100,369 |
About Immunic, Inc.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the …
Insider Activity of Immunic, Inc.
Over the last 12 months, insiders at Immunic, Inc. have bought $100,369 and sold $0 worth of Immunic, Inc. stock.
On average, over the past 5 years, insiders at Immunic, Inc. have bought $131,809 and sold $174,866 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rudick Richard Alan (director) — $100,369.
The last purchase of 87,300 shares for transaction amount of $100,369 was made by Rudick Richard Alan (director) on 2024‑11‑12.
List of Insider Buy and Sell Transactions, Immunic, Inc.
| 2024-11-12 | Rudick Richard Alan | director | 87,300 0.0969% | $1.15 | $100,369 | -5.64% | ||
| 2024-02-26 | Vitt Daniel | President and CEO | 14,000 0.0159% | $1.31 | $18,333 | -0.78% | ||
| 2023-05-15 | Whaley Glenn | Chief Financial Officer | 5,000 0.0114% | $1.75 | $8,750 | -22.16% | ||
| 2022-12-14 | Neermann Joerg | director | 47,000 0.1472% | $1.26 | $59,032 | +29.37% | ||
| 2022-12-13 | Neermann Joerg | director | 35,000 0.1105% | $1.25 | $43,610 | +31.45% | ||
| 2022-11-23 | Neermann Joerg | director | 18,000 0.0578% | $1.39 | $25,020 | +19.85% | ||
| 2022-11-22 | Vitt Daniel | President and CEO | 8,000 0.0259% | $1.35 | $10,799 | +24.43% | ||
| 2022-11-07 | Whaley Glenn | Chief Financial Officer | 5,000 0.0164% | $1.50 | $7,475 | +13.99% | ||
| 2022-06-03 | Vitt Daniel | President and CEO | 5,000 0.0151% | $3.10 | $15,500 | -43.22% | ||
| 2022-06-03 | Whaley Glenn | Chief Financial Officer | 3,500 0.0104% | $3.04 | $10,658 | -43.22% | ||
| 2022-05-12 | Muehler Andreas | Chief Medical Officer | 3,500 0.0115% | $5.10 | $17,850 | -59.81% | ||
| 2022-05-12 | Nash Duane | Executive Chairman | 10,000 0.0323% | $5.03 | $50,300 | -59.81% | ||
| 2022-05-12 | Whaley Glenn | Chief Financial Officer | 3,000 0.0098% | $5.08 | $15,240 | -59.81% | ||
| 2021-08-10 | Vitt Daniel | President and CEO | 1,000 0.0039% | $9.60 | $9,600 | -5.42% | ||
| 2021-08-10 | Nash Duane | Executive Chairman | 1,000 0.004% | $9.80 | $9,800 | -5.42% | ||
| 2021-08-10 | Whaley Glenn | PFO and PAO | 1,500 0.006% | $9.85 | $14,775 | -5.42% | ||
| 2021-05-12 | Nash Duane | Executive Chairman | 4,000 0.0186% | $12.75 | $51,000 | -21.89% | ||
| 2021-03-02 | Muehler Andreas | Chief Medical Officer | 10,006 0.046% | $15.54 | $155,493 | -34.17% | ||
| 2021-03-02 | Whaley Glenn | PFO and PAO | 1,000 0.0049% | $16.48 | $16,480 | -34.17% | ||
| 2020-08-10 | Whaley Glenn | PFO and PAO | 1,000 0.0051% | $18.96 | $18,960 | -20.03% |
Total: 81
*Gray background shows transactions not older than one year
Insider Historical Profitability
43.23%
| Rudick Richard Alan | director | 87300 0.0969% | $97,776.00 | 1 | 0 | |
| Vitt Daniel | President and CEO | 390877 0.4339% | $437,782.24 | 4 | 2 | +11.82% |
| Muehler Andreas | Chief Medical Officer | 297986 0.3308% | $333,744.32 | 2 | 0 | <0.0001% |
| Winters Terence E. | Co-Chairman and CEO | 194966 0.2164% | $218,361.92 | 2 | 0 | +75.81% |
| Neermann Joerg | director | 100000 0.111% | $112,000.00 | 3 | 0 | +26.89% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$22,597,521 | 91 | 4.59% | $109.66M | |
$7,147,964 | 34 | 24.78% | $96.35M | |
Immunic, Inc. (IMUX) | $36,079,815 | 31 | 43.23% | $100.89M |
$26,678,853 | 21 | -5.95% | $95.53M | |
$294,424,120 | 20 | 1.33% | $108.12M |
IMUX Institutional Investors: Active Positions
| Increased Positions | 32 | +48.48% | 4M | +6.44% |
| Decreased Positions | 23 | -34.85% | 9M | -14.75% |
| New Positions | 11 | New | 353,864 | New |
| Sold Out Positions | 7 | Sold Out | 266,105 | Sold Out |
| Total Postitions | 75 | +13.64% | 53M | -8.32% |
IMUX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bvf Inc/Il | $10,595.00 | 9.89% | 8.9M | 0 | 0% | 2024-12-31 |
| Avidity Partners Management Lp | $9,480.00 | 8.85% | 7.97M | -299,600 | -3.62% | 2024-12-31 |
| Soleus Capital Management, L.P. | $8,679.00 | 8.1% | 7.29M | 0 | 0% | 2024-12-31 |
| Rtw Investments, Lp | $5,436.00 | 5.08% | 4.57M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $4,669.00 | 4.36% | 3.92M | -776,253 | -16.52% | 2024-12-31 |
| Janus Henderson Group Plc | $3,200.00 | 2.99% | 2.69M | -2M | -47.27% | 2024-12-31 |
| Focus Partners Wealth | $2,580.00 | 2.41% | 2.17M | +23,610 | +1.1% | 2024-12-31 |
| Gratus Capital, Llc | $2,511.00 | 2.34% | 2.11M | +56,857 | +2.77% | 2024-06-30 |
| Omega Fund Management, Llc | $2,128.00 | 1.99% | 1.79M | 0 | 0% | 2024-12-31 |
| Ikarian Capital, Llc | $1,921.00 | 1.79% | 1.61M | +1M | +227.09% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.